Factors Influencing Urinary Symptoms 10 Years After Permanent Prostate Seed Implantation
Authors:
- Nelson N. StoneNSNelson N. Stone
- Richard G. StockRSRichard G. Stock
- Kerns SKSKerns S
- Stone NSNStone N
- Stock RSRStock R
- Rath LRLRath L
- Ostrer HOHOstrer H
- Rosenstein BRBRosenstein B
- 31 January 2012
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 187 (1) , 117-123
Abstract
Purpose: We investigated the factors that influenced urinary symptoms in the first 10 years after prostate brachytherapy. Materials and Methods: A total of 1,932 men were treated with prostate brachytherapy alone or with external beam irradiation and followed a mean of 6.8 years. The influence of pretreatment American Urological Association symptom score (7 or less, 8 to 19, 20 or greater), external beam radiotherapy, 125I or 103Pd, biological effective dose, age, prostate size and hormone therapy on the change in American Urological Association symptom score (11,491) was compared. Results: The mean change from initial score (7.4) was 11.4, 5.5, 3.3, 2.7, 1.5, 1.2, 1, 1, 1, 1, 1.3 and 1.4 points at 3, 6 months and 1 to 10 years, respectively (p <0.001). Factors that resulted in a greater increase in urinary symptoms at year 1 were low pretreatment score (p <0.001), no hormonal therapy (p <0.001), younger age (p = 0.046) and higher biological effective dose (p = 0.025). At 10 years patients with an initial score of 20 or greater had an average decrease of 11 points compared to a decrease of 0.9 for an initial score of 8 to 19 and an increase of 2.7 for an initial score of 7 or less (p <0.001). On linear regression the scores at 1 year were influenced by initial score (p <0.001), biological effective dose (p = 0.022), prostate size (p <0.001) and hormonal therapy (p = 0.009). At 10 years only the pretreatment score remained significant (p <0.001). Conclusions: There is minimal change in mean American Urological Association symptom score (1.4 points) 10 years after prostate brachytherapy. Patients presenting with high initial scores have the greatest improvement from baseline. Biological effective dose, external beam radiotherapy, hormonal therapy, isotope, patient age and prostate size do not appear to influence long-term urinary symptoms.Keywords
This publication has 29 references indexed in Scilit:
- Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy – Morbidity and outcome resultsRadiotherapy and Oncology, 2009
- Long-Term Urinary Sequelae Following 125 Iodine Prostate BrachytherapyJournal of Urology, 2008
- Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantationBJU International, 2006
- Prediction of Urinary Symptoms After 125Iodine Prostate BrachytherapyClinical Oncology, 2006
- Long-term urinary quality of life after permanent prostate brachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Predictive factors of urinary retention following prostate brachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Factors predicting for postimplantation urinary retention after permanent prostate brachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- IDENTIFICATION OF PATIENTS AT INCREASED RISK FOR PROLONGED URINARY RETENTION FOLLOWING RADIOACTIVE SEED IMPLANTATION OF THE PROSTATEJournal of Urology, 1998
- Acute urinary morbidity following I-125 interstitial implantation of the prostate glandRadiation Oncology Investigations, 1998